> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Beam Therapeutics Eyes Its First Drug Filing By Year-End As Quarterly Loss Widens To $134.4 Million
- URL: https://www.bullished.co/beam-therapeutics-eyes-its-first-drug-filing-by-year-end-as-quarterly-loss-widens-to-134-4-27cd2f70/
- Published: 2026-11-03T13:52:07.000Z
- Updated: 2026-11-03T13:52:07.000Z
- Description: The gene-editing company says cash plus a $200 million credit draw lasts into mid-2029, with cash at $1.0 billion.
- Author: Matteo Parrino
- Tags: SEC Filings, BEAM, Industry: Healthcare

[Beam Therapeutics](https://www.bullished.co/tag/beam/), which develops gene-editing medicines built on base editing, said it could file its first biologics license application, for sickle cell therapy risto-cel, [as early as year-end 2026](https://www.globenewswire.com/news-release/2026/11/03/3394035/0/en/beam-therapeutics-reports-third-quarter-2026-financial-results-and-highlights-clinical-progress-across-base-editing-portfolio.html?ref=bullished.co), while its third-quarter net loss widened to [$134.4 million](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526444454/beam-ex99%5F1.htm?ref=bullished.co), or $1.28 per share. The company reported the results Tuesday in an [8-K](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526444454/beam-20261103.htm?ref=bullished.co); a year earlier the loss was $112.6 million, or $1.10 per share.

## Revenue dried up, spending held

License and collaboration revenue fell to $307 thousand from $9.7 million a year earlier. Total operating expenses rose to $141.6 million from $136.5 million.

General and administrative costs climbed to $31.5 million from $26.7 million. Research and development was nearly flat at $110.1 million, against $109.8 million.

For the first nine months, the net loss was $351.4 million, or $3.38 per share, compared with $323.0 million, or $3.31 per share, in the same period of 2025.

## Cash into mid-2029

Cash, cash equivalents and marketable securities stood at [$1.0 billion](https://www.globenewswire.com/news-release/2026/11/03/3394035/0/en/beam-therapeutics-reports-third-quarter-2026-financial-results-and-highlights-clinical-progress-across-base-editing-portfolio.html?ref=bullished.co) on September 30, down from $1.2 billion at the end of 2025\. Beam expects that cash, plus an additional $200 million it expects to draw from its Sixth Street credit facility, to fund operations into mid-2029, assuming the conditions on those borrowings are met.

The company says that runway should carry it through a potential risto-cel launch, the pivotal plan for BEAM-302 and clinical proof of concept for BEAM-304.

## Four programs, one near a filing

Beam's lead programs include risto-cel, an investigational sickle cell therapy, and BEAM-302, a one-time treatment for alpha-1 antitrypsin deficiency, an inherited lung and liver disorder. It earns money through collaborations with drug companies including Pfizer, Apellis and Eli Lilly.

Beam expects to report updated risto-cel data by year-end 2026\. CEO John Evans said the company is "approaching a potential first BLA filing with risto-cel as early as the end of this year."

Dosing in the BEAM-302 pivotal cohort is expected to finish in the first half of 2027\. In September, Beam presented data with up to 18 months of follow-up showing durable increases in functional AAT, the protein the disease leaves deficient.

Beam also presented early data for BEAM-301, aimed at glycogen storage disease type Ia; two of three patients in the 40 mg cohort reached the protocol's maximum controlled fasting time of at least 15 hours. A 60 mg cohort is enrolling. Dosing in the BEAM-304 phenylketonuria trial is expected to start in early 2027.

In September, Beam named Eric Foster chief commercial officer.

Beam's management next appears in a fireside chat at the Guggenheim healthcare conference in Boston on Tuesday, November 10, at 9:00 a.m. ET.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Beam Therapeutics Inc. (BEAM)](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526444454/beam-20261103.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit beam-ex99\_1.htm — Beam Therapeutics Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526444454/beam-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Why Beam Therapeutics Stock Is Up 15.6% And What's Next](https://finance.yahoo.com/healthcare/articles/why-beam-therapeutics-stock-15-101413429.html?ref=bullished.co) — Yahoo Finance
- [Beam Therapeutics Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/03/3394035/0/en/beam-therapeutics-reports-third-quarter-2026-financial-results-and-highlights-clinical-progress-across-base-editing-portfolio.html?ref=bullished.co) — globenewswire.com

### More on Beam Therapeutics

- [Biogen Is Dropping Its Rights To Beam's FcRN Program, The Last Apellis Opt-In](https://www.bullished.co/biogen-is-dropping-its-rights-to-beams-fcrn-program-the-last-apellis-opt-in-6b628112/)

[All Beam Therapeutics (BEAM) coverage →](https://www.bullished.co/tag/beam/)